For research use only. Not for therapeutic Use.
Dual PPARα/γ agonist, and potent inhibitor of melanogenesis by inhibition of mushroom tyrosinase activity (IC50 value 8.19 μM). MHY908 more potently activated PPARα and PPARγ than fenofibrate and rosiglitazone, respectively, and enhanced the binding and transcriptional activity of PPARα and -γ in AC2F cells. It reduced serum glucose, triglyceride, and insulin levels, however increased adiponectin levels without body weight gain. In addition, MHY 908 significantly improved hepatic steatosis by enhancing CPT-1 levels. Remarkably, MHY-908 reduced endoplasmic reticulum (ER) stress and c-Jun N-terminal kinase (JNK) activation, and subsequently reduced insulin resistance.
| Catalog Number | R065755 |
| CAS Number | 1393371-39-5 |
| Molecular Formula | C17H14ClNO3S |
| Purity | ≥95% |
| IUPAC Name | 2-[4-(5-chloro-1,3-benzothiazol-2-yl)phenoxy]-2-methylpropanoic acid |
| InChI | InChI=1S/C17H14ClNO3S/c1-17(2,16(20)21)22-12-6-3-10(4-7-12)15-19-13-9-11(18)5-8-14(13)23-15/h3-9H,1-2H3,(H,20,21) |
| SMILES | CC(C)(C(=O)O)OC1=CC=C(C=C1)C2=NC3=C(S2)C=CC(=C3)Cl |
| Reference | M.H. Park et al. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice. PLoS One. 2013 Nov 14;8(11):e78815.
M.H. Park et al. Inhibition of melanogenesis by 2-[4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy]-2-methylpropanoic acid (MHY908). Arch Pharm Res. 2014 Dec 14. [Epub ahead of print] |
